Shire beats Street as Adderall sales rise 42%

Shire (LSE:SHP; SHPGY) reported first quarter non-GAAP earnings per ADS of $0.44, beating by $0.06 the Street's estimate of $0.38 and up 46% from $0.30 in the first quarter of 2005. The increase was driven by gains in revenues, which rose 23% to $411 million, including $206.1 million in sales of ADHD drug Adderall XR, which was a 42% increase over the prior year's quarter. ...